#USA #New York #ALS #ProJenX #Prosetin

ProJenX Provides Promising Update on Prosetin for ALS Treatment

ProJenX, a clinical-stage biotechnology firm, recently disclosed significant developments regarding prosetin, a novel treatment aimed at addressing amyotrophic lateral sclerosis (ALS) and other serious neurodegenerative disorders. The update follows the completion of the Phase 1b clinical trial, labeled PRO-101, assessing prosetin, a CNS-penetrant MAP4K inhibitor, in ALS patients.

Clinical Study Overview

The PRO-101 study focused on evaluating prosetin's safety, tolerability, pharmacokinetics, and target engagement. Encompassing 41 ALS participants, the trial investigated varying dosages of prosetin and reported encouraging safety profiles across all levels tested, ranging from 0.16 mg/kg/day to 1.05 mg/kg/day. Importantly, no serious adverse events related to prosetin have been recorded up to this stage. This finding is crucial as it underscores the drug's viability for longer-term administration.

Efficacy and Pharmacokinetics

Interim results indicate that prosetin can consistently achieve the targeted therapeutic concentration necessary for potential therapeutic effectiveness. Statistical evidence suggests that increased exposure to prosetin corresponds with a significant decrease in phosphorylated MAP2K4 (pMAP2K4) levels in the participants’ peripheral blood mononuclear cells (PBMCs). This decrease in pMAP2K4, a protein associated with neuroinflammation in ALS, suggests that prosetin effectively engages its target, aligning with preclinical findings indicating its neuroprotective properties in ALS models.

Dr. Jinsy Andrews, a leading researcher at NYU Langone ALS Center, expressed optimism about the findings, mentioning that the study successfully answered pivotal questions regarding prosetin's safe administration in ALS patients.

Continuing Evaluations and Future Directions

As the MAD segment of PRO-101 successfully concludes, ProJenX is dedicated to further exploring prosetin's long-term effects via a two-year open-label extension (OLE) study. This phase involves tracking the health of the participants from the initial study while evaluating additional safety, tolerability, and pharmacokinetic data. Exploring biomarkers such as neurofilament light chain (NfL) and neuroinflammatory indicators will also provide insights into prosetin's impact on ALS and aid in refining future clinical trial designs.

Erin Fleming, Co-Founder and COO of ProJenX, indicated that the OLE data will directly influence upcoming clinical studies, helping establish rigorous eligibility criteria and study endpoints for a comprehensive Phase 2 trial. The company aims to position prosetin as a scientifically-grounded treatment for individuals living with ALS.

Upcoming Presentation

Key interim study results from PRO-101 are scheduled to be presented at the European Network to Cure ALS (ENCALS) meeting from June 24-26 in Madrid, Spain. This event will illuminate further insights into the research and ongoing efforts to bring prosetin to the forefront of ALS treatments.

Summary

Prosetin stands to revolutionize ALS therapies due to its potential as a disease-modifying treatment. Built upon a robust research collaboration between Project ALS and Columbia University, ProJenX continues to lead innovative strategies to combat ALS and similar brain-related ailments. However, it is essential to note that prosetin remains an investigational product, pending FDA approval.

For more information on ProJenX and prosetin, please explore their website at projenx.com.